Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy.

25 In contrast to the current study, in which the incidence of treatment‐emergent nausea was significantly lower for DPOS vs placebo, the difference in incidence for triptan treatments vs placebo, with the exception of sumatriptan 25 mg, did not reach statistical significance. 25 In this study nausea was reported as an AE at similar low frequencies for DPOS and placebo (4% and 3%, respectively).

also in 111,027 other papers